Paul J. Sekhri Sells 1,107 Shares of Veeva Systems Inc (VEEV) Stock

Share on StockTwits

Veeva Systems Inc (NYSE:VEEV) Director Paul J. Sekhri sold 1,107 shares of Veeva Systems stock in a transaction that occurred on Monday, June 25th. The shares were sold at an average price of $82.80, for a total value of $91,659.60. Following the completion of the transaction, the director now owns 11,432 shares in the company, valued at $946,569.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Veeva Systems opened at $76.20 on Friday, Marketbeat.com reports. Veeva Systems Inc has a 1-year low of $52.17 and a 1-year high of $85.00. The company has a market capitalization of $10.81 billion, a P/E ratio of 82.83, a price-to-earnings-growth ratio of 4.17 and a beta of 1.42.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings results on Thursday, May 24th. The technology company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Veeva Systems had a return on equity of 12.47% and a net margin of 20.78%. The firm had revenue of $195.55 million for the quarter, compared to the consensus estimate of $188.92 million. During the same period in the previous year, the business earned $0.24 earnings per share. The company’s revenue for the quarter was up 22.4% compared to the same quarter last year. research analysts anticipate that Veeva Systems Inc will post 1.02 EPS for the current year.

Several research analysts have weighed in on VEEV shares. ValuEngine upgraded Veeva Systems from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Needham & Company LLC lifted their target price on Veeva Systems to $90.00 and gave the company a “buy” rating in a research note on Friday, May 25th. Canaccord Genuity lifted their target price on Veeva Systems from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, May 25th. Zacks Investment Research upgraded Veeva Systems from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Thursday, May 31st. Finally, SunTrust Banks started coverage on Veeva Systems in a research note on Monday. They issued a “buy” rating and a $100.00 target price on the stock. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $79.34.

A number of institutional investors and hedge funds have recently bought and sold shares of VEEV. We Are One Seven LLC boosted its position in Veeva Systems by 147.6% during the first quarter. We Are One Seven LLC now owns 1,679 shares of the technology company’s stock worth $123,000 after purchasing an additional 1,001 shares in the last quarter. Next Century Growth Investors LLC purchased a new stake in Veeva Systems during the first quarter worth $130,000. American International Group Inc. purchased a new stake in Veeva Systems during the fourth quarter worth $142,000. Diversified Trust Co purchased a new stake in Veeva Systems during the first quarter worth $200,000. Finally, Synovus Financial Corp purchased a new stake in Veeva Systems during the first quarter worth $201,000. Institutional investors own 72.92% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, and internationally. The company offers Veeva Commercial Cloud, a suite of multichannel customer relationship management applications, which allow pharmaceutical and biotechnology companies to target and support sales and marketing to physicians, other healthcare professionals, and healthcare organizations through various touch points, including in-person, email, and online; and Veeva Vault, a cloud-based enterprise content management platform and suite of applications for managing commercial functions, including medical, sales, and marketing, as well as research and development functions, such as clinical, regulatory, and quality.

Insider Buying and Selling by Quarter for Veeva Systems (NYSE:VEEV)

Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply